Skip to main content
Equibles
CTOR logo

CTOR · Citius Oncology, Inc. · Metrics

Track CTOR — free

Use CTOR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CTOR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.85 -0.10 (-10.52%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We will need to raise additional capital to support our operations beyond November 2026, which raises substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$94.92M
Shares
92.98M
Volume · Oct 5 85.51K Avg daily vol (3M) 100.01K

CTOR metrics

47 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.95
Market cap
$94.92M

Price action

20 metrics
Price change (1W)
-9.5%
Price change (30D)
+2.3%
Price change (3M)
+39.7%
Price change (6M)
+35.1%
Price change (YTD)
-5.0%
Price change (1Y)
-49.5%
Trailing year
Price change (5Y)
—
52-week high
$1.89
52-week low
$0.49
Change from 52-week high
-49.7%
Change from 52-week low
+92.7%
Annualized volatility
91.5%
Annualized volatility (3M)
98.0%
Beta
1.9
RSI (14D)
50.8
Price vs SMA 50
+14.8%
Price vs SMA 200
+8.4%
Avg volume (3M)
100,006
Relative volume
2.1
Average dollar volume
$83,313

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
92.98M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.4
reciprocal yield 42.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-48.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$47.29M
Net income (TTM)
−$46.06M
Trailing 12 months
Diluted EPS (TTM)
$-0.47
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.54

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+50.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-114.1%
Return on assets
-41.1%
Debt / equity
—
Current ratio
0.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$16.56M
Latest balance sheet
Cash & equivalents
$16.56M
Total assets
$112.09M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
$3.39M
SG&A (TTM)
—
Stock compensation (TTM)
$13.34M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
19
13F filer change QoQ
+5
Institutional ownership
15.2%

Short interest

3 metrics
Short interest
0.5%
Latest settlement · 6.9 days to cover
Days to cover
6.9d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1851484 CUSIP 17331Y109 13F (30d) 1 filings 1 filers Visit website